Search Results

Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete

concept of biased agonism has been effectively leveraged in drug discovery, as demonstrated by the development By selectively targeting specific signaling pathways, it is possible to develop drugs with improved efficacy

Although several B2R agonists and antagonists have been developed, icatibant is the only B2R antagonist

Recently, several high-throughput screening (HTS) assays for ERK activation have been developed, each In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new

, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development

Essential to the further development of such applications, however, is a clearer understanding of how

ligands acting on neurotransmitter receptors have shown great potential for inhibiting GBM growth and development

biochemical and structural studies of class IB phosphoinositide 3-kinases There is considerable interest in developing work reveals insight into PI3Kγ regulation and identifies sites that may be exploited for therapeutic development

dysregulation of TLR4 contributes to numerous diseases, which highlights the importance of biased modulator development The discovery of biased modulators of TLR4 would provide insight for the future development of biased

"We are an experienced, innovative, global team on a bold mission to improve health by creating and developing

These complex properties have driven the need for development of specialized tools that can sense neuropeptide

As new technologies are developed and applied to studying GPCR structure and their downstream effectors

Sosei Heptares, which have struck a research agreement to discover new GPCR targets that’ll fuel the development

approved drugs over previous decades—but the two-year-old biotech believes the area is still ripe for development

Research Collaboration Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

In a constant effort to develop drugs with less side effects, and tools to explore the ORs nature and

GPCR Binders, Drugs, and more Persistent challenges in the development of an mGlu7 PAM in vivo tool compound Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

recognizes the combination of Steyaert’s fundamental research and his ability to apply the research to the development

biopharmaceutical company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel

Encouraging Phase 1 results and supportive preclinical package assist in the launch of Phase 2 clinical development

Drugs, and more Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability BioSpace Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

protein-coupled receptors helps in elucidating the metabolic pathways involved in metabolic dysfunction and in developing

Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential. Antibody Engineering Scientist—Immuno-Oncology Convergent Research - Senior Scientist, Cell-Based Assay Development

Recently, AlphaFold2 has been developed to predict structure models of many functionally important proteins

One potential solution is to develop analgesics that act at targets other than opioid receptors.

findings provide new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development

However, the drug development of CX3CR1 is hampered partially by the lack of structural information.

For GPCR assay developers, HCS supports:  Quantitative visualization of receptor internalization and fluorescent ligand technologies without needing internal imaging infrastructure or specialized assay development

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel